Ceryvyn Therapeutics ASX:CYV Return-on-Tangible-Asset is -59.76% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 84.04% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ceryvyn Therapeutics‘s annualized Net Income for the quarter that ended in Jun. 2025 was A$-94.84 Mil. Ceryvyn Therapeutics‘s average total tangible assets for the quarter that ended in Jun. 2025 was A$158.71 Mil. Therefore, Ceryvyn Therapeutics‘s annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2025 was -59.76%.
The historical rank and industry rank for Ceryvyn Therapeutics‘s Return-on-Tangible-Asset or its related term are showing as below:
During the past 13 years, Ceryvyn Therapeutics‘s highest Return-on-Tangible-Asset was -16.85%. The lowest was -182.73%. And the median was -49.35%.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically “derive their value from legal or intellectual rights.” Return-on-Tangible-Asset measures a firm’s efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Ceryvyn Therapeutics Return-on-Tangible-Asset Related Terms
Ceryvyn Therapeutics Return-on-Tangible-Asset Historical Data
The historical data trend for Ceryvyn Therapeutics‘s Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company’s associated stock exchange currency.
Ceryvyn Therapeutics Return-on-Tangible-Asset Chart
ASX:CYV vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics‘s Return-on-Tangible-Asset, along with its competitors’ market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that “N/A” values will not show up in the chart.
Ceryvyn Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics‘s Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics’s Return-on-Tangible-Asset falls into.
Ceryvyn Therapeutics Return-on-Tangible-Asset Calculation
Ceryvyn Therapeutics‘s annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2025 is calculated as:
Ceryvyn Therapeutics‘s annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company’s associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2025) net income data.
What does a Return-on-Tangible-Asset of -59.76% mean?
Ceryvyn Therapeutics (ASX:CYV) has a Return-on-Tangible-Asset of -59.76% as of Jun. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #1190 out of 1416 companies in the Biotechnology industry, placing it in the top 84%.
Is Ceryvyn Therapeutics’ Return-on-Tangible-Asset too high?
Ceryvyn Therapeutics’ current Return-on-Tangible-Asset is -59.76%. Based on the distribution chart, Ceryvyn Therapeutics ranks #1190 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics’ Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #1190 out of 1416 companies for Return-on-Tangible-Asset. This places Ceryvyn Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Return-on-Tangible-Asset of -59.76%. The current Return-on-Tangible-Asset is -59.76%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Ceryvyn Therapeutics Business Description
Address
C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Leave a comment